Company: CERO
Filing Date: 2025-05-07
Form Type: DEF 14A
Source: 0001213900-25-040263
Chunk: 133

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-07
Form: DEF 14A
Chunk 133
---
ii) 9,660shares of Common Stock, held by the Kathleen LaPorte Revocable Trust, of which Ms. LaPorte serves as a trustee, and (iii) 7,498shares of Common Stock issuable pursuant to stock options exercisable within 60 days of May 1, 2025. (8)Consists of 7,498shares of Common Stock issuable pursuant to stock options exercisable within 60 days of May 1, 2025. (9)Consists of 6,284shares of Common Stock issuable pursuant to stock options exercisable within 60 days of May 1, 2025. 76 REPORT OF THE AUDIT COMMITTEE The audit committee has reviewed our audited consolidated financial statements for the fiscal year ended December 31, 2024 and discussed them with the Company’s management and Wolf, the Company’s independent registered public accounting firm. The audit committee has also received from, and discussed with, Wolf various communications that Wolf is required to provide to the audit committee, including the matters required to be discussed by the applicable requirements of the Public Company Accounting Oversight Board and the SEC. In addition, Wolf provided the audit committee with the written disclosures and the letter required by applicable requirements of the Public Company Accounting Oversight Board regarding the independent registered public accounting firm’s communications with the audit committee concerning independence, and has discussed with the Company’s independent registered public accounting firm their independence. Based on the review and discussions referred to above, the audit committee recommended to the board of directors that the audited consolidated financial statements be included in the Company’s Annual Report on Form 10 -Kfor the year ended December 31, 2024. By the audit committee of the board of directors of CERo Therapeutics Holdings, Inc. Michael Byrnes
Lindsey Rolfe
Shami Patel March31, 2025 This report shall not be deemed to be “soliciting material” or to be “filed” with the SEC, nor shall such information be incorporated by reference into any filing of CERo Therapeutics Holdings, Inc. with the SEC, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing, or subject to the liabilities of Section 18 of the Exchange Act. 77 DELINQUENT SECTION 16(A) REPORTS Section 16(a) of the Exchange Act requires our directors and executive officers, and persons who beneficially own more than 10% of